Cost Analysis of Aprotinin Reintroduction in French Cardiac Surgery Centres: A Real-World Data-Based Analysis

INTRODUCTION: The European Medicines Agency restored aprotinin (APR) use for preventing blood loss in patients undergoing isolated coronary artery bypass graft (iCABG) in 2016 but requested the collection of patient and surgery data in a registry (NAPaR). The aim of this analysis was to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Colson, Pascal, Fellahi, Jean-Luc, Gaudard, Philippe, Provenchère, Sophie, Rozec, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070296/
https://www.ncbi.nlm.nih.gov/pubmed/36867329
http://dx.doi.org/10.1007/s12325-023-02464-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070296/
https://www.ncbi.nlm.nih.gov/pubmed/36867329
http://dx.doi.org/10.1007/s12325-023-02464-7

Ejemplares similares